India, Oct. 14 -- Takeda Pharmaceutical Company Ltd. (TAK,4502.T), which explores orexin science, announced on Thursday that ORZEYFUL (oveporexton) is now available in Japan and China to treat Narcolepsy Type 1 (NT1), with clinicians gaining first access to prescribe this new class of medicine.
Narcolepsy Type 1 (NT1) is a chronic, rare neurological disorder caused by a deficiency of orexin, a brain chemical that helps regulate wakefulness. The condition is characterised by excessive daytime sleepiness and a range of other symptoms, including cataplexy (sudden loss of muscle control triggered by emotions), disrupted nighttime sleep, sleep paralysis, hallucinations, and cognitive difficulties that can affect daily functioning.
ORZEYFUL (ov...